title: IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome.
abstract: OBJECTIVE
  Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome related to insulin resistance. Insulin-like growth factor 1 (IGF-1) is mainly produced by hepatocytes and its secretion is stimulated by growth hormone. Our aim was to assess possible changes in IGF-1 levels in patients with different ultrasonography stages of NAFLD and its association with hyperlipidemia, impaired glucose tolerance, non-insulin dependant type 2 diabetes, waist circumference, obesity and arterial hypertension.
  
  
  METHODS
  One hundred and ten consecutive patients were evaluated.
  
  
  RESULTS
  IGF-1 levels decreased as liver steatosis worsened. There was a statistically significant difference between mild-moderate steatosis on one hand, and severe steatosis on the other (142 vs. 110, P < 0.05). Homeostasis model assessment of insulin resistance (HOMA) and insulin levels showed a tendency to inverse association with IGF-1, but it was not statistically significant. HOMA significantly increased in severe liver steatosis when compared with mild-moderate steatosis (6.20 vs. 3.99, P < 0.05). Insulin levels also showed a significant increase (3.01 +/- 0.61 vs. 2.59 +/- 0.56, P < 0.05). Body mass index showed a significant inverse correlation with IGF-1 level (r = -0.19, P < 0.05) and a tendency to increase as liver steatosis worsened. Waist circumference increased significantly as liver steatosis worsened (severe vs. mild-moderate: 114 vs. 100, P < 0.05).
  
  
  CONCLUSIONS
  IGF-1 levels showed a decrease as liver steatosis worsened. This difference was statistically significant between mild-moderate and severe stetaosis. Inverse correlation between IGF-1 levels and BMI was also statistically significant. There was no statistically significant correlation between IGF-1 levels and HOMA and insulin levels.
authors.affiliation: Servicio de Endocrinología, Hospital Militar Central, Ciudad Autónoma de Buenos Aires, Argentina. smalleagil@gmail.com
authors.forename: María Susana
authors.initials: MS
authors.lastname: Mallea-Gil
authors.forename: María Carolina
authors.initials: MC
authors.lastname: Ballarino
authors.forename: Adriana
authors.initials: A
authors.lastname: Spiraquis
authors.forename: Mariel
authors.initials: M
authors.lastname: Iriarte
authors.forename: Marta
authors.initials: M
authors.lastname: Kura
authors.forename: Silvia
authors.initials: S
authors.lastname: Gimenez
authors.forename: Adriana
authors.initials: A
authors.lastname: Oneto
authors.forename: Mirtha
authors.initials: M
authors.lastname: Guitelman
authors.forename: Rogelio
authors.initials: R
authors.lastname: Machado
authors.forename: Carlos Mariano
authors.initials: CM
authors.lastname: Miguel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005234:Fatty Liver / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers; D007334:Insulin-Like Growth Factor I